Chemotherapy for advanced non-small cell lung cancer

Hematology/Oncology Clinics of North America

Volumn 11, Issue 3, 1997, Pages 473-517

  Herbst, R S ^a   Dang, N H ^a   Skarin, A T ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; NAVELBINE; PROCARBAZINE; VINBLASTINE; VINDESINE;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0030993682     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70445-7     Document Type: Article

References (207)

1. R.P. Abratt W.R. Bezwoda G. Falkson Efficacy and safety profile of gemcitabine in non–small-cell lung cancer: A Phase II study J Clin Oncol 12 1994 1535
2. K.S. Albain J.J. Crowley M.N. LeBlanc Survival determinants in extensive non-small cell lung cancer: The Southwest Oncology Group experience J Clin Oncol 9 1991 1618 1625
3. R.P. Abratt W.R. Bozwoda L. Goedhals Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small cell lung cancer J Clin Oncol 15 1977 744 749
4. W. Akerley M. Glantz H. Choy Preliminary results of a Phase I study of weekly paclitaxel infusion in patients with non–small cell lung cancer Semin Oncol 23 1996 14 18
5. H. Anderson B. Lund F. Bach Single-agent activity of weekly gemcitabine in advanced non–small-cell lung cancer: A phase II study J Clin Oncol 12 1994 1821
6. H. Anderson N. Thatcher J. Walling Gemcitabine and palliation of symptoms in nonsmall cell lung cancer [abstract 1238] Proc Am Soc Clin Oncol 13 1994 367
7. A. Anton A. Carrato Gonzalex Larriba J.L. Phase II activity of gemcitabine in combination with cisplatin in advanced non–small cell lung cancer [abstract 1134] Proc Am Soc Clin Oncol 15 1996 380
8. S.G. Arbuck Paclitaxel What schedule? What dose? J Clin Oncol 12 1994 233 236
9. A. Ardizzoni V. Fusco M. Gusliiano Etoposide, ifosfamide, and cisplatin in the treatment of advanced non–small cell lung cancer Cancer Treat Rep 71 1987 1311 1312
10. C.P. Belani Multimodality management of regionally advanced non–small lung cancer Semin Oncol 20 1993 302
11. C.P. Belani J. Aisner D. Hiponia Paclitaxel and carboplatin in metastatic non–small cell lung cancer: Preliminary results of a Phase I study Semin Oncol 23 1996 19 21
12. L. Belli T. LeChevalier M. Gottfried Phase I–II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non–small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 14 1995 750
13. S. Binet E. Chaineau A. Fellous Immunofluorescence study of the action of Navelbine, vincristine and vinblastine on mitotic and axonal microtubules Int J Cancer 46 1990 262 266
14. J.F. Bishop J. Zalchung L.K. Webster A phase I trial of the combination of taxotere and cisplatin in patients with advanced non-small cell lung cancer [abstract] Lung Cancer 11 suppl 1994 124
15. Bitran JD, Desser RK, Demeester T: Cyclophosphamide, Adriamycin, methotrexate and procarbazine (CAMP)—effective four-drug combination chemotherapy for metastatic non–oat cell bronchogenic carcinoma.
16. P. Bonomi Carboplatin in non–small cell lung cancer: Review of the Eastern Cooperative Oncology Group Trial and comparison with other carboplatin trials Semin Oncol 18 1991 2 7
17. P.D. Bonomi D. Finkelstein J. Ruckedschel Combination chemotherapy versus single agents followed by a combination chemotherapy in stage IV non–small-cell lung cancer. A study of the Eastern Cooperative Oncology Group J Clin Oncol 7 1989 1602 1613
18. P. Bonomi K. Kim A. Chang Phase III trial comparing etoposide, cisplatin vs. Taxol/cisplatin in advanced non–small cell lung cancer [abstract 1145] Proc Am Soc Clin Oncol 15 1996 382
19. C.C. Boring T.S. Squires T. Tong Cancer statistics, 1994 CA Cancer J Clin 44 1994 7
20. J.C. Brittell T. Eagan N. Ingle cis-Dichlorodiammineplatinum alone followed by Adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum, Adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung Cancer Treat Rep 62 1978 1207 1210
21. G.F. Buccheri D. Ferrigno A. Curcio Continuation of chemotherapy vs supportive care alone in patients with inoperable non–small cell lung cancer and stable disease after two or three cycles of MACC Cancer 63 1989 428 432
22. Bunn PA Jr: New drug combinations in the treatment of advanced non–small cell (NSCLC) and small cell (SCLC) lung cancer. 1996.
23. Bunn P.A. Jr The expanding role of cisplatin in the treatment of non–small cell lung cancer Semin Oncol 16 suppl 6 1986 1 12
24. P.A. Bunn Clinical experiences with carboplatin (Paraplatin) in lung cancer Semin Oncol 19 suppl 2 1992 1 11
25. Bunn P.A. Jr The treatment of non–small cell lung cancer: Current perspectives and controversies, future directions Semin Oncol 21 1994 49
26. Bunn P.A. Jr K. Kelly A phase I study of carboplatin and paclitaxel in non–small cell lung cancer: A University of Colorado Cancer Center study Semin Oncol 22 suppl 9 1995 2 6
27. H.A. Burris M.L. Rothenberg J.G. Kuhn Clinical trials with topoisomerase I inhibitors Semin Oncol 19 1992 663
28. H. Burris J. Eckhardt S. Fields Phase II trials of taxotere in patients with non–small cell lung cancer [abstract 1116] Proc Am Soc Clin Oncol 12 1993 335
29. A.H. Calvert D.R. Newell L.A. Gumbrell Carboplatin dosage: Prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1989 1748 1756
30. G. Carteri F. Cartel A. Cantone Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non–small cell lung cancer J Natl Cancer Inst 85 1993 794 800
31. D.F. Cella D.S. Tulsky G. Gray The functional assessment of cancer therapy scale: Development and validation of the general measure J Clin Oncol 11 1993 570
32. R. Cellerino D. Tummarello F. Guidi A randomized trial of alternating chemotherapy versus best supportive care in advanced non–small cell lung cancer J Clin Oncol 9 1991 1453 1461
33. T. Cerny S. Kaplan N. Pavlidis Docetaxel (Taxotere) is active in non–small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 1994 384
34. A.P. Chahinian E.M. Mandel J.F. Holland MACC (methotrexate, Adriamycin, cyclophosphamide and CCNU) in advanced lung cancer Cancer 43 1979 1590 1597
35. A.Y. Chang K. Kim J. Glick Phase II study of Taxol, merbarone, and piroxantrone in Stage IV non–small-cell lung cancer: The Eastern Cooperative Oncology Group results J Natl Cancer Inst 85 1993 388
36. A.Y. Chang G.C. Garrow Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer Semin Oncol 22 suppl 5 1995 66 71
37. H. Choy W. Akerley M. Safarin Phase I trial of paclitaxel and thoracic radiation in NSCLC J Clin Oncol 12 1994 2682 2686
38. A. Coates V. Gebski D. Signorevi Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer patients J Clin Oncol 10 1992 1833
39. J.T. Cole R.J. Gralla C.B. Marques Phase II study of cisplatin + docetaxel (taxotere) in nonsmall cell lung cancer (NSCLC) [abstract 1087] Proc Am Soc Clin Oncol 14 1995 357
40. Y. Cormier D. Bergeron J. LaForge Benefit of polychemotherapy in advanced non–small cell bronchogenic carcinoma Cancer 50 1982 845 848
41. J. Crawford M. O'Rourke J.H. Schiller Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer J Clin Oncol 14 1996 2774 2780
42. L. Crino G. Scagliotti M. Marangolo Cisplatin-gemcitabine combination in advanced nonsmall cell lung cancer. A phase II study J Clin Oncol 15 1997 297 303
43. S. Davis P. Rambotti Y.K. Park Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non–small cell carcinoma of the lung Cancer Treat Rep 65 1981 955 958
44. A. Depierre E. Lemarie G. Dabouis A phase II study of Navelbine in the treatment of non–small-cell lung cancer Am J Clin Oncol 14 1991 115
45. A. Depirre C. Chasting E. Quoix Vinorelbine versus vinorelbine plus cisplatin in advanced NSCLC: A randomized trial Oncology 5 1994 37 42
46. Depierre A. Le Beau B. C. Chasting Results of a phase II randomized study of vinorelbine-cisplatin in non–small cell lung cancer Proc Am Soc Clin Oncol 12 1993 340
47. R. DeVore J. Hainsworth F.A. Greco Chronic oral etoposide in the treatment of lung cancer Semin Oncol 19 S14 1992 28 35
48. H.M. Dhingra M. Valdivieso D.T. Carr Randomized trial of three combinations of cisplatin with vindensine and/or VP-16 213 in the treatment of advanced non–small cell lung cancer J Clin Oncol 3 1985 176 183
49. D.J. Dunlop C. Cameron G. Dabouis Phase I dose-escalation study of cisplatin in combination with gemcitabine in non–small cell lung cancer [abstract 1139] Proc Am Soc Clin Oncol 13 1994 342
50. Eagan RF, Ingle JN, et al: Platinum based polychemotherapy versus dianhydrogalactitol in advanced non–small cell lung cancer. Cancer Treat Rep 61:1339–1345,
51. L.H. Einhorn K. Pennington J. McClean Phase II trial of daily oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology Group Study Semin Oncol 17 1990 32
52. P.A. Ellis I.E. Smith J.R. Hardy Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non–small-cell lung cancer Br J Cancer 71 1995 366 370
53. D.S. Ettinger Ifosfamide in the treatment of non–small cell lung cancer Semin Oncol 16 suppl 3 1989 31 38
54. W.K. Evans R. Feld G. DeBoer Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non–small cell bronchogenic carcinoma Cancer Treat Rep 65 1981 947 954
55. W.K. Evans B.P. Will Berthelot J.-M. M.C. Wolfson Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model Can J Oncol 5 1995 408 419
56. W.K. Evans Management of metastatic non–small cell lung cancer and a consideration of cost Chest 103 1993 685
57. W.K. Evans D.J. Stewart E. Tamiak Carboplatin (C) and paclitaxel (P) by one hour infusion for advanced non–small cell lung cancer (NSCLC) [abstract 1156] Proc Am Soc Clin Oncol 14 1995 374
58. E.G. Feigal M. Christian B. Cheson New chemotherapeutic agents in non–small-cell lung cancer Semin Oncol 20 1993 185
59. R. Feld L. Rubinstein P.A. Thomas Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non–small-cell lung cancer J Natl Cancer Inst 85 1993 299
60. C. Fernandez R. Rossell A. Abad-Esteve Quality of life during chemotherapy in non–small cell lung cancer patients Acta Oncol 28 1989 129 133
61. D.M. Finkelstein D.S. Ettinger J.C. Ruckdeschel Long-term survivors in metastatic non–small cell lung carcinoma: An Eastern Cooperative Oncology Group study J Clin Oncol 4 1986 702 709
62. F.V. Fossella S. Lippman A. Pang Phase I gemcitabine by 30 minute weekly intravenous infusion 3 wks every 4 wks for non–small cell lung cancer [abstract 1082] Proc Am Soc Clin Oncol 12 1993 326
63. Fossella F.V. Soo Lee J. D.M. Shin Phase II study of docetaxel for advanced or metastatic platinum-refractory non–small-cell lung cancer J Clin Oncol 13 1995 645
64. F.V. Fossella J.S. Lee J. Berille Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non–small cell lung cancer Semin Oncol 22 S4 1995 22 29
65. Fossella F.V. Soo Lee J. W.K. Murphy Phase II study of docetaxel for recurrent or metastatic non–small-cell lung cancer J Clin Oncol 12 1994 1238
66. P.A. Francis J.R. Rigas M.G. Kris Phase II trial of docetaxel in patients with stage III and IV non–small-cell lung cancer J Clin Oncol 12 1994 1232
67. M. Fukuoka H. Nitani A. Suzuki A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non–small-cell lung cancer J Clin Oncol 10 1992 16 20
68. D.R. Gandara H. Wold E.A. Perez Cisplatin dose intensity in non–small cell lung cancer: Phase II results of a day 1 and day 8 high-dose regimen J Natl Cancer Inst 81 1989 790 794
69. D.R. Gandara J. Crowley R.B. Livingston Evaluation of cisplatin intensity in metastatic non–small cell lung cancer: A phase III study of the Southwest Oncology Group J Clin Oncol 11 1993 873 878
70. P.A. Ganz R.A. Figlin C.M. Haskel Supportive care versus supportive care and combination chemotherapy in metastatic non–small cell lung cancer Does chemotherapy make a difference? Cancer 63 1989 1271 1278
71. V. Gatzemeier M. Heckmayr D. Hossfield A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non–small cell lung cancer Am J Clin Oncol (CCT) 14 1991 405
72. U. Gatzemeier M. Heckmayer R. Neuhauss Chemotherapy of advanced inoperable non–small cell lung cancer with paclitaxel: A phase II trial Semin Oncol 22 1995 24 28
73. V. Gatzemeier M. Heckmayer R. Neuhauss Phase II study with paclitaxel for the treatment of advanced inoperable non–small cell lung cancer Lung Cancer 12 1995 101 106
74. V. Gatzemeier M. Heckmayer Phase II study with paclitaxel in advanced inoperable nonsmall cell lung cancer (NSCLC). The European experience. Lung Cancer The Journal of the International Association for the Study of Lung Cancer II suppl 2 1994 236
75. M.S. Georgiadis J.E. Brown B.S. Schinler Phase I study of a four day continuous infusion of paclitaxel followed by cisplatin in patients with advanced lung cancer Proc Am Soc Clin Oncol 14 1995 353
76. G. Giaccone M. Huizing P.E. Postmus Dose-finding and sequencing study of paclitaxel and carboplatin in non–small cell lung cancer Semin Oncol 22 suppl 9 1995 78 82
77. R.J. Gralla E.S. Casper D.P. Kelsen Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules Ann Intern Med 95 1981 414
78. M.R. Green Multimodality therapy for solid tumors N Engl J Med 330 1994 206
79. M.R. Green New directions for chemotherapy in non–small cell lung cancer Chest 103 1993 370S
80. M.R. Green H. Kreisman D.C. Doll Carboplatin in non–small cell lung cancer: An update on the Cancer and Leukemia Group B experience Semin Oncol 19 S3 1992 44 49
81. M.R. Green H. Kreisman D.C. Doll Carboplatin in non–small cell lung cancer: An update on the Cancer and Leukemia Group B experience Semin Oncol 19 suppl 2 1992 44 49
82. R. Grilli A.D. Oxman J.A. Julian Chemotherapy for advanced non–small-cell lung cancer: How much benefit is enough? J Clin Oncol 11 1993 1866
83. J.D. Hainsworth D.A. Thompson F.A. Greco Paclitaxel by 1-hour infusion: An active drug in metastatic non–small cell lung cancer J Clin Oncol 13 1995 1609 1614
84. J.D. Hainsworth P. Miller A. Menchise Treatment of locally advanced non–small cell lung cancer with Taxol (1-hour infusion), cisplatin, etoposide, and radiation therapy: A phase II trial [abstract] Proc Am Soc Clin Oncol 13 1994 350
85. J.D. Hainsworth L. Hopkins M. Thomas Taxol administered by one-hour infusion: Preliminary results of a phase I/II study comparing two dose schedules [abstract] Lung Cancer 11 suppl 11 1994 96
86. J.D. Hainsworth D.S. Thompason W.J. Urba One hour paclitaxel plus carboplatin in advanced non–small cell lung cancer (NSCLC): Preliminary results of a multi-institutional phase II study [abstract 1131] Proc Am Soc Clin Oncol 15 1996 379
87. J.R. Hardy T. Noble I.E. Smith Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non–small cell lung cancer Br J Cancer 60 1989 764
88. T.S. Herman S.E. Jones L.J. McMahon Combination chemotherapy with Adriamycin and cyclophosphamide (with or without radiation therapy) for carcinoma of the lung Cancer Treat Rep 61 1977 875
89. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen
90. V.K. Israel S. Zaretsky R.B. Natale Phase I/II trial of combination carboplatin and Taxol in advanced non–small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 13 1994 A351
91. L. Jaakkimainen P.J. Goodwin J. Pater Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non–small-cell lung cancer J Clin Oncol 8 1990 1301
92. P. Jacoulet A. Dubiez A. DePierre One week versus 3-week intervals in the administration of cisplatin in combination with Vinorelbine: A randomized study in non–small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 11 1992 301
93. D. Johnson D.M. Paul K.R. Hande Paclitaxel plus carboplatin in advanced non–small cell lung cancer: A Phase II trial J Clin Oncol 14 1996 2054 2060
94. D.H. Johnson Overview of ifosfamide in small cell and non–small cell lung cancer Semin Oncol 17 S4 1990 24 30
95. A. Kaasa E. Lund E. Thorod Symptomatic treatment versus combination chemotherapy in patients with non–small cell lung cancer extensive disease Cancer 67 1991 2443 2447
96. J. Klastersky Therapy with cisplatin and etoposide for NSCLC Semin Oncol 13 1986 104 114
97. J. Klastersky J.P. Sculier G. Bureau Cisplatin versus cisplatin plus etoposide in the treatment of advanced non–small cell lung cancer J Clin Oncol 7 1989 1087 1092
98. J. Klastersky J.P. Sculier P. Ravez A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non–small cell lung carcinoma J Clin Oncol 4 1986 1780 1786
99. J. Klastersky J.P. Sculier H. Lacroix A randomized study comparing cisplatin or carboplatin plus etoposide in patients with advanced non–small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 17861 J Clin Oncol 8 1990 1556 1562
100. J. Klastersky J.P. Sculier Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non–small cell lung cancer Lung Cancer 12 suppl 2 1995 S117 S125
101. J.A. Knost F.A. Greco K.R. Hande Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non–small cell lung cancer Cancer Treat Rep 65 1981 941 945
102. M. Kris R. Gralla M. Wetheim Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non–small cell lung cancer Cancer Treat Rep 70 1986 1091 1096
103. M.G. Kris R.J. Gralla L.A. Kalman A randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment Cancer Treat Rep 69 1985 387 395
104. Kris M. Gralla R.J. Potanovich L. Assessment of pretreatment symptoms and improvement after EDAM + mitomycin + vinblastine in patients with inoperable non–small cell lung cancer Proc Am Soc Clin Oncol 9 1990 229 [abstract 883]
105. M.G. Kris R.J. Gralla L.M. Potanovich Long term survival analysis of stage III and IV non–small cell lung cancer patients treated with edatrexate [abstract 408] Lung Cancer 7 1991 111
106. S. Lai L.J. Goldstein M.M. Gottesman MDR 1 gene expression in lung cancer J Natl Cancer Inst 81 1989 1144
107. C.J. Langer J. Leighton R. Comis Taxol and carboplatin in combination in stage IV and IIIB non–small cell lung cancer (NSCLC): A phase II trial [abstract] Proc Am Soc Clin Oncol 13 1994 338
108. C.J. Langer J.C. Leighton R.L. Comis Paclitaxel and carboplatin in combination in the treatment of advanced non–small-cell lung cancer: A phase II toxicity, response, and survival analysis J Clin Oncol 12 1995 1860 1870
109. Le Chevalier T. Chemotherapy for advanced NSCLC. Will meta-analysis provide the answer? Chest 109 1996 107S
110. Le Chevalier T. M. Gottfried M. Gatzemier Confirmatory activity of gemcitabine in non–small cell lung cancer Eur J Cancer 29 suppl 6 1993 160
111. Le Chevalier T. L. Belli A. Monnier Phase II study of docetaxel (Taxotere) and cisplatin in advanced nonsmall cell lung cancer (NSCLC): An interim analysis [abstract 1059] Proc Am Soc Clin Oncol 14 1995 350
112. Le Chevalier T. D. Brisgand J.V. Douillard Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non–small-cell lung cancer: Results of a European Multicenter Trial including 612 patients J Clin Oncol 12 1994 360
113. J.S. Lee H.I. Libshitz W.K. Murphy Phase II study of 10-ethyl-10-deazaaminopterine (10-EDAM; CGP 30 694) for stage IIIB or IV non–small cell lung cancer Invest New Drugs 8 1990 299
114. J.S. Lee H.I. Libshitz W.K. Murphy Phase II study of 10-ethyl-10-deazaaminopterin for stage IIIB or IV non–small cell lung cancer Invest New Drugs 8 1990 299 304
115. W.T. Leung W.C.T. Shiu J.C.K. Pang Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non–small cell lung cancer Oncology 49 1992 321 326
116. J.E. Liebmann J.A. Cook C. Lipschultz Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines Br J Cancer 68 1993 1104 1109
117. R.C. Lilenbaum M.R. Green Novel chemotherapeutic agents in the treatment of non–small cell lung cancer J Clin Oncol 11 1993 1391 1402
118. R.C. Lilenbaum M.R. Green Multimodality treatment of non–small cell lung cancer Oncology 8 1994 25 31
119. E. Longeval J. Klastersky Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma Cancer 50 1982 2751 2756
120. D.W. Luedke L. Einhorn G. Omura Randomized comparison of two combination chemotherapy regimens versus minimal chemotherapy in non–small cell lung cancer: A Southeastern Cancer Study Group trial J Clin Oncol 8 1990 886 891
121. T.J. Lynch F. Kass L.A. Kalish Cisplatin, 5-fluorouracil, and etoposide for advanced non–small cell lung cancer Cancer 7 1993 2953
122. T.J. Lynch L. Kalish G. Strauss Phase II study of topotecan in metastatic non–small-cell lung cancer J Clin Oncol 12 1994 347
123. W.J. Mackillop B. O'Sullivan G.K. Ward Non–small-cell lung cancer: How oncologists want to be treated Int J Radiat Oncol Biol Phys 13 1987 929
124. P. Marino S. Pampallona A. Preatoni Chemotherapy vs supportive care in advanced non–small-cell lung cancer. Results of a meta-analysis of the literature Chest 106 1994 861
125. N. Masuda M. Fukuoka M. Takada CPT-11 in combination with cisplatin for advanced non–small-cell lung cancer J Clin Oncol 10 1992 1775 1780
126. N. Masuda M. Fukuoka S. Kudoh Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony stimulating factor support for advanced lung cancer J Clin Oncol 12 1994 1833 1841
127. J.G. McVie Chemotherapy for advanced disease. How to raise enthusiasm Chest 109 1996 80S
128. T.P. Miller T.T. Chen C.A. Coltman Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group study J Clin Oncol 4 1986 502 508
129. M.J. Millward J. Zalchberg J.F. Bishop Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer J Clin Oncol 15 1997 750 758
130. 2 with prednisone premedication in nonsmall cell lung cancer (NSCLC) [abstract 1226] Proc Am Soc Clin Oncol 13 1994 364
131. C.F. Mountain A new international staging system for lung cancer Chest 89 suppl 1986 225S 233S
132. C.F. Mountain The new international staging system for lung cancer Surg Clin North Am 67 1987 925
133. C.F. Mountain Lung cancer staging classification Clin Chest Med 14 1993 43
134. F.M. Muggia D. Vafai R. Natale Paclitaxel 3-hour infusion given alone and combined with carboplatin: Preliminary results of dose-escalation trials Semin Oncol 22 1995 63 65
135. W.K. Murphy F.V. Fossella R.J. Winn Phase II study of Taxol in patients with untreated advanced non–small-cell lung cancer J Natl Cancer Inst 8 1993 384
136. K. Nakagawa M. Fukuoka H. Nutani Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non–small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 12 1993 A1104
137. R.B. Natale A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non–small cell lung cancer: Preliminary results of an ongoing study Semin Oncol 22 suppl 15 1995 34 37
138. R.B. Natale Preliminary results of a Phase I/II clinical trial of paclitaxel and carboplatin in non–small cell lung cancer Semin Oncol 23 1996 2 6
139. S. Negoro M. Fukuoka N. Masuda Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non–small-cell lung cancer J Natl Cancer Inst 83 1991 1164
140. S. Negoro M. Fukuoka Y. Kurita Results of phase II studies of gemcitabine in non–small cell lung cancer [abstract] Proc Am Soc Clin Oncol 13 1994 367
141. J.P. O'Connell M.G. Kris R.J. Gralla Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non–small lung cancer treated with combination chemotherapy J Clin Oncol 4 1986 1604 1614
142. M. O'Rourke J. Crawford J. Schiller Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine in randomized controlled trial [abstract 1148] Proc Am Soc Clin Oncol 12 1993 343
143. A. Paccagnella A. Favaretto A. Brandes Cisplatin, etoposide, and ifosfamide in non–small cell lung carcinoma Cancer 65 1990 2631 2634
144. D.M. Paul R. DeVore K.R. Hande Phase I trial of carboplatin and paclitaxel in advanced non–small cell lung cancer [abstract 1103] Proc Am Soc Clin Oncol 14 1995 361
145. R. Perez-Soler B.S. Gibson J. Kane Phase II study of topotecan in patients with non–small cell lung cancer previously untreated [abstract 1114] Proc Am Soc Clin Oncol 13 1994 363
146. Perez-Soler R, Fossella FV, Glisson BS, et al: Phase II study of topotecan in patients with advanced non–small cell lung cancer previously untreated with chemotherapy. J Clin Oncol, in press
147. P.E. Postmus G. Giaccone C. Debryune Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non–small cell lung cancer Semin Oncol 23 1996 10 13
148. P. Pronzato M. Landucci F. Vaira Failure of vinorelbine to produce responses in pretreated non–small cell lung cancer patients Anticancer Res 14 1994 1413 1416
149. E. Quoix A. Dieterman J. Charbonneau Disseminated non–small cell lung cancer: A randomized trial of chemotherapy versus palliative care Lung Cancer 4 1988 A181
150. E. Rapp J.L. Pater A. Willan Chemotherapy can prolong survival in patients with advanced non–small-cell lung cancer—report of a Canadian multicenter randomized trial J Clin Oncol 6 1988 633
151. Richards F. II D.J. Perry M. Goutsou Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non–small cell lung cancer Cancer 67 1991 2974
152. J.R. Rigas P.A. Francis M.G. Kris Phase II trial of Taxotere in non–small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 12 1993 336
153. V. Roa A. Conner R.B. Mitchell Carboplatin and paclitaxel for advanced non–small cell lung cancer in previously treated patients [abstract] Proc Am Soc Clin Oncol 15 1996 403
154. R. Rosell A. Abad-Esteve L. Moreno A randomized comparison of two vindesine plus cisplatin containing regimens with the addition of mitomycin or ifosfamide in patients with non–small cell lung cancer Lung Cancer 4 1988 120
155. R. Rosell J. Gomez-Codina C. Camps A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non–small cell lung cancer N Engl J Med 330 1994 153
156. J. Roth F. Fossella R. Komaki A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer J Natl Cancer Inst 88 1994 673
157. E.K. Rowinsky M.R. Gilbert W.P. McGuire Sequences of Taxol and cisplatin: A phase I and pharmacologic study J Clin Oncol 9 1991 1692 1703
158. E. Rowinsky R.C. Donehauer Vinca alkaloids and epipodophyl-toxins Perry M.C. The Chemotherapy Source Book 1992 Williams & Wilkins Baltimore 359 383
159. E.K. Rowinsky L.B. Grochow C.B. Hendricks Phase I and pharmacologic study of topotecan: A novel topoisomerase inhibitor J Clin Oncol 10 1992 647 656
160. E.K. Rowinsky V. Chaudhry A.A. Forastiiere Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting J Clin Oncol 11 1993 2010 2020
161. E. Rowinsky K. Sartorious M.K. Bowling Paclitaxel on a 3-hour schedule and carboplatin in non–small cell lung cancer; use of maximally tolerated and clinically relevant single-agent doses in combination is feasible [abstract 1075] Proc Am Soc Clin Oncol 14 1995 354
162. E.K. Rowinsky N. Onetto R.M. Cannetta Taxol: The first of the taxanes, an important new class of antitumor agents Semin Oncol 19 1992 646
163. J.C. Ruckdeschel Etoposide in the management of non–small cell lung cancer Cancer 67 S 1991 250 253
164. J.C. Ruckedschel D.M. Finkelstein D.S. Ettinger A randomized trial of the most active regimens for metastatic non–small cell lung cancer J Clin Oncol 4 1986 14 22
165. J. Ruckedschel D. Finkelstein D. Ettinger A randomized trial of the four most active regimens for metastatic non–small cell lung cancer J Clin Oncol 4 1986 14 22
166. J. Ruckdeschel H. Wagner C. Williams Second-line chemotherapy for resistant metastatic non–small cell lung cancer: The role of Taxol [abstract] Proc Am Soc Clin Oncol 13 1994 357
167. J.C. Ruckdeschel S. Piantadose Assessment of quality of life by functional living index–cancer (FLIC) is superior to performance status for prediction of survival in patients with lung cancer Proc Am Soc Clin Oncol 8 1989 311
168. V. Rusch D. Klimstra E. Venkatraman Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non–small cell lung cancer Cancer Res 55 1995 5038
169. A.B. Sandler R. Ansari J. McClean Cisplatin-gemcitabine combination in nonsmall cell lung cancer [abstract 1089] Proc Am Soc Clin Oncol 14 1995 357
170. Saxman S. Loehrer P.J. Sr K. Logie Phase II trial of daily oral etoposide in patients with advanced non–small cell lung cancer: A phase trial Invest New Drugs 9 1991 253 256
171. J.H. Schiller B. Storer J. Berlin Amifostine, cisplatin, and vinblastine in metastatic non–small cell lung cancer: A report of high response rates and prolonged survival J Clin Oncol 14 1996 1912 1921
172. O.S. Selawry The role of chemotherapy in the treatment of lung cancer Semin Oncol 1 1974 259
173. K.V. Shepherd H.M. Golomb J.D. Bitran CAMP chemotherapy for metastatic non–oat cell bronchogenic carcinoma Cancer 56 1985 2385 2390
174. F. Shepherd Y. Cormier R. Burkes Phase I study of gemcitabine and cisplatin for advanced non–small cell lung cancer [abstract] Lung Cancer 11 suppl 1994 116
175. F.A. Shepherd Treatment of advanced non–small cell lung cancer Semin Oncol 21 1994 7
176. F.A. Shepherd U. Gatzemeier M. Gotfried An extended phase II study of gemcitabine in nonsmall cell lung cancer (NSCLC) [abstract 1096] Proc Am Soc Clin Oncol 12 1993 330
177. Y. Shimada M. Yostino A. Wakui Phase II Study of CPT-11, a new camptothecin derivative, in patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 10 1991 135
178. T. Shinkai H. Arioka H. Kunikane A phase I study of CPT-11 and cisplatin in combination with a fixed dose of vindesine in metastatic non–small cell lung cancer [abstract 1089] Proc Am Soc Clin Oncol 12 1993 328
179. T. Shinkai H. Arioka H. Kunikane Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-peperidino)-1-piperidino] carbonyloxy-campthothecin and cisplatin in combination with fixed dose of vindesine in advanced non–small cell lung cancer Cancer Res 54 1994 2636 2642
180. A. Skarin M. Jochelson T. Sheldon Neoadjuvant chemotherapy in marginally resectable stage III Mo non–small cell lung cancer: Long-term follow-up in 41 patients J Surg Oncol 40 1989 266 274
181. W.J. Slichenmyer E.K. Rowinsky R.C. Donehower The current status of camptothecin analogues as antitumor agents J Natl Cancer Inst 85 1993 271 291
182. J.B. Sorensen K. Osterlind H.H. Hansen Vinca alkaloids in the treatment of non–small cell lung cancer Cancer Treat Rev 14 1987 29 41
183. J.B. Sorenson A.L. Nielsen M. Krarup Phase II study of gemcitabine plus vindesine in patients with previously untreated inoperable non–small cell lung cancer Lung Cancer 11 suppl 1994 116
184. J.B. Sorenson H.H. Hansen P. Dombernowsky Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs J Clin Oncol 5 1987 1169 1177
185. R.L. Souhami R.M. Rudd S.G. Spiro Phase II study of edatrexate in stage III and IV non–small cell lung cancer Cancer Chemother Pharmacol 30 1992 465 468
186. P.J. Souquet F. Chauvin J.P. Boissel Polychemotherapy in advanced non–small cell lung cancer: A meta-analysis Lancet 342 1993 19
187. R.C. Spain The case for mitomycin in non–small cell lung cancer Oncology 50 suppl 1 1993 35 52
188. K.E. Stanley Prognostic factors for survival in patients with inoperable lung cancer J Natl Cancer Inst 65 1980 25 32
189. L.A. Stewart Chemotherapy in non–small cell lung cancer: A meta-analysis using update data on individual patients from 52 randomised clinical trials Br Med J 311 1995 899
190. M.J. Straus Combination chemotherapy in advanced lung cancer with increased survival Cancer 38 1976 2232
191. S. Takeuchi H. Takamizawa Y. Takeda Clinical study of CPT-11, a camptothecin derivative, on gynecological malignancy Proc Am Soc Clin Oncol 10 1991 189
192. W. Tester J. Cohn A. Desai Phase II study of short infusion paclitaxel in patients with stage IV nonsmall cell lung cancer [abstract 1189] Proc Am Soc Clin Oncol 14 1995 382
193. N. Thatcher R.M. Niven H. Anderson Aggressive vs nonaggressive therapy for metastatic NSCLC Chest 109 1996 87S 92S
194. neu levels in HER-2/neu-transfected human lung cancer cells J Natl Cancer Instit 87 1995 82
195. D. Vafai V. Israel S. Zaretsky Phase I/II trial of combination carboplatin and Taxol in non–small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 14 1995 352
196. M.H. Veeder J.R. Jett J.Q. Su A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma Cancer 70 1992 2281 1187
197. N.J. Vogelzang P.D. Bonomi A.H. Rossof Cyclophosphamide, Adriamycin, methotrexate and procarbazine (CAMP) treatment of non–oat cell bronchogenic carcinoma Cancer Treat Rep 62 1978 1595 1597
198. S.E. Vogi C.R. Mehta M.H. Cohen MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung. Low response rate in a cooperative group study Cancer 44 1979 864 868
199. E. Vokes R. Rosenberg M. Jahenzelo Multicenter study of oral navelbine (NVB) in previously untreated stage IV non–small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 12 1993 336
200. Von Pawel J. H. Wagner N. Niederle Paclitaxel and cisplatin in patients with non–small cell lung cancer: Results of a Phase II trial Semin Oncol 23 1996 7 9
201. T.M. Waits D.H. Johnson J.D. Hainsworth Prolonged administration of oral etoposide in non–small cell lung cancer: A phase II trial J Clin Oncol 1992 292 296
202. K. Watanabe A. Yokoyama K. Furuse Phase II trial of docetaxel in previously untreated nonsmall cell lung cancer (NSCLC) [abstract 1095] Proc Am Soc Clin Oncol 13 1994 331
203. J. Weeks Quality-of-life assessment: Performance status upstaged? J Clin Oncol 40 1992 1827
204. J. Weick J. Crowley R. Natale A randomized trial of five cisplatin-containing treatments in patients with metastatic non–small cell lung cancer. A Southwest Oncology Group Study J Clin Oncol 9 1991 1157 1162
205. J.J. Weitz S.H. Jung R.F. Marschke Randomized phase II trial of two schedules of totecan for the treatment of advanced stage non–small cell lung carcinoma (NSCLC): A North Central Cancer Treatment Group (NCCTG) trial [abstract] Proc Am Soc Clin Oncol 14 1995 348
206. R.L. Woods C.J. Williams J. Levi A randomized trial of cisplatin and vindesine versus supportive care only in advanced non–small cell lung cancer Br J Cancer 61 1990 608 611
207. A.J. Wozniak J.J. Crowley S.P. Balcerzak Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non–small cell lung cancer (NSCLC): Report of a Southwest Oncology Group Study (SWOG-9308) [abstract 1110] Proc Am Soc Clin Oncol 15 1996 374